Aspire-Lakewood Holdings, Inc.

Aspire Biopharma is an early-stage biopharmaceutical company developing and commercializing a proprietary sublingual drug delivery technology that enables rapid, pH-neutral absorption of medications under the tongue, bypassing the gastrointestinal tract to reduce side effects and improve therapeutic impact. The company's lead product is a prescription-strength sublingual aspirin formulation for acute cardiovascular events, with a pipeline that includes melatonin, vitamins, caffeine, and other nutraceuticals and pharmaceuticals based on the same delivery platform. Aspire generates revenue through direct product sales of approved drugs and nutraceuticals, licensing and collaboration agreements with pharmaceutical partners (including upfront fees, milestone payments, and royalties), and manufacturing partnerships with third-party contract manufacturers; the company retains U.S. commercial rights for its pharmaceutical candidates and plans to build a focused sales organization for specialty care markets while pursuing international partnerships for certain products.